Karyopharm Therapeutics Inc. (KPTI) Stock Price

KPTIStock

$0.39−93.53%52W

Market Cap$8.85M

P/E—

PEG Ratio—

Div yield—

Beta1.18

KPTI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-105.29%

Price vs S&P 500 (4W)-77.70%

VGM Score45.96

Book Value / Share (Quarterly)$0.68

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.40%

Cash Flow / Share (Quarterly)$-2.88

Price vs S&P 500 (YTD)-106.63%

Gross Margin (TTM)95.89%

Net Profit Margin (TTM)-153.28%

EPS (TTM)$-12.84

10-Day Avg Trading Volume1.46M

EPS Excl Extra (TTM)$-12.84

Revenue Growth (5Y)6.21%

EPS (Annual)$-17.93

ROI (Annual)-81.28%

Gross Margin (Annual)95.93%

Net Profit Margin (5Y Avg)-89.84%

Cash / Share (Quarterly)$2.87

Revenue Growth QoQ (YoY)-11.86%

ROA (Last FY)-180.82%

Revenue Growth TTM (YoY)6.81%

EBITD / Share (TTM)$-7.45

ROE (5Y Avg)-210.81%

Operating Margin (TTM)-98.70%

Cash Flow / Share (Annual)$-4.12

P/B Ratio0.17x

P/B Ratio (Quarterly)22.52x

Net Income / Employee (Annual)$-859,800

EV / Revenue (TTM)1.88x

Net Interest Coverage (TTM)-3.55x

ROA (TTM)-200.94%

EPS Incl Extra (Annual)$-17.93

Current Ratio (Annual)1.12x

Quick Ratio (Quarterly)0.71x

3-Month Avg Trading Volume1.44M

52-Week Price Return-93.53%

Revenue / Employee (TTM)$643,100

Tangible BV / Share (Quarterly)$-0.88

P/S Ratio (Annual)0.06x

Asset Turnover (Annual)1.35x

52-Week High$10.99

Operating Margin (5Y Avg)-76.47%

EPS Excl Extra (Annual)$-17.93

CapEx CAGR (5Y)-7.53%

26-Week Price Return-95.38%

Quick Ratio (Annual)0.98x

13-Week Price Return-95.90%

Total Debt / Equity (Annual)3.78x

Current Ratio (Quarterly)0.79x

Enterprise Value$276.15M

Revenue / Share Growth (5Y)54.83%

Asset Turnover (TTM)1.31x

Book Value / Share Growth (5Y)-34.14%

Revenue / Employee (Annual)$640,600

Inventory Turnover (Annual)1.36x

Pretax Margin (Annual)-134.18%

Cash / Share (Annual)$3.48

3-Month Return Std Dev193.11%

Gross Margin (5Y Avg)96.70%

Net Income / Employee (TTM)$-985,700

ROE (Last FY)-388.71%

Net Interest Coverage (Annual)-3.79x

EPS Basic Excl Extra (Annual)$-17.93

Receivables Turnover (TTM)4.67x

Total Debt / Equity (Quarterly)3.78x

EPS Incl Extra (TTM)$-12.84

Receivables Turnover (Annual)5.13x

ROI (TTM)-66.32%

P/S Ratio (TTM)0.06x

Pretax Margin (5Y Avg)-89.70%

Revenue / Share (Annual)$13.36

Tangible BV / Share (Annual)$-0.15

Price vs S&P 500 (52W)-109.06%

Year-to-Date Return-94.70%

5-Day Price Return-22.77%

EPS Normalized (Annual)$-17.93

ROA (5Y Avg)-74.72%

Net Profit Margin (Annual)-134.21%

Month-to-Date Return-68.02%

Cash Flow / Share (TTM)$-1.29

EBITD / Share (Annual)$-13.97

Operating Margin (Annual)-104.80%

LT Debt / Equity (Annual)3.78x

ROI (5Y Avg)-79.29%

LT Debt / Equity (Quarterly)3.78x

EPS Basic Excl Extra (TTM)$-12.84

P/B Ratio (Annual)22.52x

Inventory Turnover (TTM)1.34x

Pretax Margin (TTM)-153.30%

Book Value / Share (Annual)$0.68

Price vs S&P 500 (13W)-98.58%

Beta1.18x

Revenue / Share (TTM)$5.07

ROE (TTM)-182.43%

52-Week Low$0.31

vGradeA

gGradeC

mGradeF

vgmGradeC

KPTI Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$1.39	-$2.32	-66.91%(-$0.93)
Q1 2026	May 14, 2026	-$1.44	-$1.24	+14.09%(+$0.20)
Q4 2025	Feb 12, 2026	-$2.00	-$2.23	-11.36%(-$0.23)
Q3 2025	Nov 3, 2025	-$3.25	-$3.82	-17.54%(-$0.57)
Q2 2025	Aug 11, 2025	-$3.91	-$4.07	-4.04%(-$0.16)

KPTI Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.15

4.00

4.09

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
KPTIKaryopharm Therapeutics Inc.	A	C	F	0.1x	6.8%	95.9%	—	$0.39
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics is a commercial-stage pharmaceutical company specializing in cancer drugs that inhibit nuclear export. The company's lead product, XPOVIO (selinexor), targets exportin 1 (XPO1), preventing the transport of cancer-promoting proteins out of the cell nucleus. This mechanism represents a novel approach to disrupting cancer cell survival.

KPTI Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$1.31

Revenue estimate$33.54M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

KPTI Insider Transactions

SellSep 1, 2026
ABATE KRISTIN
Officer
Shares: 19Value: $38
SellJul 28, 2026
POULTON STUART
Officer
Shares: 189Value: $1,342

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

INTSIntensity Therapeutics, Inc. Common stockBiological Products
BNKKBonk, Inc. Common StockCosmetics & Toiletries
BONBon Natural Life Limited Class A Ordinary SharesPharmaceutical Preparations
TANHTantech Holdings Ltd. Class A Common SharesIndustrial Chemicals
BMRABIOMERICA INCIn Vitro Diagnostics
FRTTFort Technology Inc. Common SharesAgricultural Chemicals
NAIINatural Alternatives International Inc.Pharmaceutical Preparations
SNTISenti Biosciences Holdings, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$0.31

High$10.99